VEGFA and hepatocellular carcinoma: This finding is consistent with a previous study showing that sorafenib is more sensitive to HCC cells with VEGF gene amplification [44], which may be due to VEGF modulating the efficacy of sorafenib treatment in the forms of autocrine or paracrine secretion [45,46].